Northwest Biotherapeutics NWBO

OTC: NWBO | ISIN: US66737P6007   6/01/2026
0,285 USD (-10,91%)
(-10,91%)   6/01/2026
Grafiek Northwest Biotherapeutics Grafiek Northwest Biotherapeutics

Northwest Biotherapeutics in het nieuws

20 november 2025 · Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility · Persbericht

24 oktober 2025 · Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed · Persbericht

27 augustus 2025 · Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd. · Persbericht

18 augustus 2025 · Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman · Persbericht

11 juni 2025 · Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments · Persbericht

3 juli 2024 · Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities · Persbericht

17 juni 2024 · Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property · Persbericht

21 maart 2024 · Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors · Persbericht

6 februari 2024 · Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification · Persbericht

21 december 2023 · Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma · Persbericht

Mijn selecties